Billionaire Boys Club Member Forum (BBCMF)

[mick]

combining information for HEMISPHERX BIOPHARMA ,


Posted bhttp://www.investorshub.com/boards/read_msg.asp?message_id=8078491y: mick
In reply to: None Date:10/11/2005 7:45:08 PM
Post #of 71352

i can only tell WHAT I READ AND SEE FOR HEB ,,, HEB.

http://search.yahoo.com/search?p=aronex&sm=Yahoo%21+Search&fr=FP-tab-web-t&toggle=1&....

Antigenics to Acquire Aronex

26 Apr 2001

Antigenics Inc. and Aronex Pharmaceuticals, Inc. have announced that they have entered into a definitive agreement for Antigenics to purchase Aronex Pharmaceuticals in a tax-free, stock-for-stock transaction.

Under the terms of the merger agreement, each outstanding share of Aronex Pharmaceuticals common stock will convert into the right to receive approximately $1.10 in shares of Antigenics common stock.

In addition, each share of Aronex Pharmaceuticals common stock will be entitled to a contingent value right potentially worth an additional $0.15. Based upon yesterday's closing price, Antigenics would issue approximately 1.8 million shares at the closing of the transaction. Pursuant to the merger agreement, stockholders of Aronex Pharmaceuticals will not receive greater than 0.0917 shares or less than 0.0550 shares of Antigenics common stock for each of their Aronex Pharmaceuticals shares.

The transaction, which has been approved by the boards of directors of both companies, will broaden and accelerate Antigenics' product pipeline with six drugs in late-stage development and one marketed product. These include a liposome-encapsulated form of all-trans-retinoic acid (ATRAGEN®) for the treatment of leukemia and a liposome- encapsulated form of nystatin (Nyotran®) for the treatment of fungal infections.

"Combining Antigenics' world-class immune technology platforms with Aronex Pharmaceuticals' liposome encapsulation technology accelerates our goal to become a diverse biopharmaceutical company with a deep arsenal of effective and safe therapies for serious human diseases," said Garo H. Armen, Ph.D., chairman and CEO of Antigenics. "The advanced stage of Aronex Pharmaceuticals' drugs will accelerate Antigenics' drive towards commercialization. We expect the merger to be accretive to our earnings starting in 2003 and enhance value for both companies' shareholders."

Geoffrey F. Cox, Ph.D., Aronex Pharmaceuticals' chairman and CEO, expressed enthusiasm for the transaction. "The resources and skill set of Antigenics should result in an accelerated advancement of our products and technologies. This merger combines two innovative companies with complementary technology platforms and common commercialization goals."

Antigenics is developing immune-based therapies of cancer, infections and autoimmune diseases using its proprietary technology platforms.

Aronex Pharmaceuticals is a biopharmaceutical company that develops proprietary innovative medicines to treat cancer and infectious diseases.


related companies
Aronex Pharmaceuticals Inc
related areas in the company directory
Sector: Pharmaceutical
Sector: Pharmaceutical: Prescription
Sector: Biotechnology
Sector: Biotechnology: Human therapeutics
Therapeutic target: Cancer


deals reviewyour essential access to biopharma deal announcements back to 1999 - search and browse deals by therapy, industry sector and company name - more information
Copyright © 1995-2005 Bridgehead International, all rights reserved. No part of this publication may be redistributed in any form without prior permission.
Terms and conditions for users Privacy policy Use of cookies Contact Us Site Map

...............................................................
THE ABOVE WAS PLACED BECAUSE SOME WHERE I THOUGHT ARONEX HAD AMPLIGEN.
...............................................................
HEB AMPLIGEN.
http://search.yahoo.com/search?p=AMPLIGEN&prssweb=Search&ei=UTF-8&fr=FP-tab-web-t&fl....

http://news.search.yahoo.com/news/search?prssweb=Search&ei=UTF-8&fl=0&fr=FP-tab-web-t&am....

News Results
Got feedback? | Suggest a Site
BLOGS BETA 1-2 of 2
Hemispherx collaborates with Japanese on...

Pharmaceutical Business Review Online
7 days ago
Hemispherx Biopharma is to collaborate w...

Add to My Yahoo! - SaveAmpligen receives increased attention in...

Avian Flu - What we need to know
8 days ago
Hemispherx Biopharma, Inc (AMEX: HEB) ha...

Add to My Yahoo! - SaveMore Blog results...
NEWS ALERTS
Alert me when articles match all these words: ampligen
ADD TO MY YAHOO! / RSS
Add your news search for ampligen to My Yahoo!:


View as RSS: NEWS STORIESResults 1 - 9 of about 9 for ampligen.Sort Results by: Relevance | Date
Hemispherx Biopharma Signs Letter of Intent With HollisterStier Laboratories LLC for the Production of Ampligen(R)
RedNova - Oct 10 9:15 AM
Hemispherx Biopharma, Inc. (AMEX: HEB) has signed a Letter of Intent (LOI) with HollisterStier Laboratories of Spokane, Washington, for the contract manufacturing of Hemispherx's experimental drug, Ampligen(R).
Save to My Web
Manufacturing facility expanded for production of Ampligen
Logistics Management - Oct 10 6:33 AM
2005 OCT 7 - (NewsRx.com) -- Hemispherx Biopharma, Inc., (HEB) disclosed by letter to stockholders that it has increased the capacity of its facility in New Brunswick, New Jersey, to manufacture its experimental drug, Ampligen, as well as advancements in the application of Alferon LDO for the potential treatment of Avian influenza.
Save to My Web
Business Editors/Health/Medical Writers
Logistics Management - Oct 11 6:17 AM
Biopharma, Inc. (AMEX: HEB ) has signed a Letter of Intent (LOI) with HollisterStier Laboratories of Spokane, Washington, for the contract manufacturing of Hemispherx's experimental drug, Ampligen(R). The achievement of the initial objectives described in the LOI, in combination with the Polymer production facility under construction in New Brunswick, N.J., will enable Hemispherx to manufacture
Save to My Web
Hemispherx Biopharma Signs Research Agreement With Japanese National Institute of Infectious Disease; Ampligen(R)
RedNova - Oct 03 8:03 AM
Hemispherx Biopharma, Inc (AMEX: HEB) has signed a research agreement with the National Institute of Infectious Diseases, in Tokyo, Japan.
Save to My Web
Hemispherx Biopharma Signs Research Agreement with Japanese National Institute of Infectious Disease
[Press Release] Business Wire via Yahoo! Finance - Oct 03 5:56 AM
Hemispherx Biopharma, Inc has signed a research agreement with the National Institute of Infectious Diseases, in Tokyo, Japan. The collaboration, by Hideki Hasegawa, M.D., Ph.D., Chief of the Laboratory of Infectious Disease Pathology, will assess Hemispherx' experimental therapeutic Ampligen as an adjuvant to the Institution's nasal flu vaccine.
Save to My Web
New Drug Helps Cope With Chronic Fatigue
CBS News - Sep 30 9:00 AM
An experimental new drug called Ampligen has shown promise in providing relief for sufferers of chronic fatigue syndrome, a debilitating disease that effects nearly a million people in the U.S.
Save to My Web
Japanese institute to test use of Phila. company's drug
bizjournals.com via Yahoo! Finance - Oct 03 7:35 AM
Hemispherx Biopharma Inc. said Monday it signed a research agreement with the National Institute of Infectious Diseases of Tokyo.
Save to My Web
Hemispherx Biopharma Signs Letter of Intent with HollisterStier Laboratories LLC for the Production of Ampligen(R)
[Press Release] Business Wire via Yahoo! Finance - Oct 10 5:30 AM
Hemispherx Biopharma, Inc. has signed a Letter of Intent with HollisterStier Laboratories of Spokane, Washington, for the contract manufacturing of Hemispherx's experimental drug, Ampligen.
Save to My Web
Japanese institute to test use of Phila. company's drug
Philadelphia Business Journal - Oct 03 7:45 AM
Hemispherx Biopharma Inc. said Monday it signed a research agreement with the National Institute of Infectious Diseases of Tokyo.
................................................................

http://www.ncf-net.org/forum/ampligeninPink.htm

Ampligen in the Pink

By Tom Windler

Pharmaceutical firms receive "The Pink Sheet" which keeps them abreast of all new happenings in the field. In March, Hemispherx BioPharma made the copy since they have an upcoming filing with the Federal Trade Commission (FDA). Ampligen has been promoting itself as the greatest hope for those with chronic fatigue syndrome for well over a decade although their own patent exposed that it revs up the tumor necrosis factor (TNF) which is not what you'd want to have done.

CFS (ME) is not the only illness that Hemispherx is running trials with. They also are testing it on metastic renal carcinoma, HIV, hepatitis B, Hepatitis C, and Hodgkin's lymphoma. It is a drug in search of an illness. Have they found the illness? The Centers for Disease Control and Prevention (CDC) has a website where they report about some adverse events, such as liver damage, is "still completely characterized." Patients have reported, for years, that the drug has caused many more adverse reactions and some have even found that, although they applied for the trial and were given a diagnosis of "CFS", they had other problems and not that illness. One found sleep apnea was the only problem! Many have been told that they are improving based upon testing results but that they were not tested. Some have been shown Karnofsky scales that were not valid. A few have found they did have some improvement.

The drug has had a checkered past. The FDA put the drug on hold in 1991 during the Phase II trials due to concerns of hepatic toxicity, severe abdominal pain and irregular heartbeat. The manufacturer, who called themselves HEM Pharmaceuticals, solved that problem by hiring a PR firm! Indeed, the next year, the FDA allowed Phase II/III to proceed and they were allowed to charge for a "cost-recovery" price. In 1998, they were again cited by the FDA. This time they were slapped for illegally promoting Ampligen as safe and effective for CFS and for other illnesses.

Hemispherx has made friends in Congress, finding the money they gained from desperate patients and other means could buy influence. Representative James Greenwood (R-PA) and Representative Joe Barton (R-TX) have been staunch allies. Hemispherx also hired those most polictically active in the field to be on their various boards such as Anthony Komaroff, M.D., a member of the CFSAC, Staci Stephens, a member of the CFSAC, and Charles Lapp, M.D., a member of the CFSAC.

Hemispherx is already counting on FDA approval and is building a marketing team in this country. They acquired a Alferon N Injection from Interferon Biosciences just last year and have already contracted with nearly 100 sales representatives.

While the FDA representative at the first CFSAC meeting said "about 20" drugs were in the pipeline for CFS, Ampligen appears to be the only one. While I, for one, have spoken to too many patients who found the drug a terrible experience, FDA approval would not change my mind. A treatment that is based upon an unknown cause does not impress me. Even those physicians who insist it has efficacy seem to be monetarily rewarded by Hemispherx. If politics wins over real science, Ampligen will win FDA approval soon. Unfortunately, it usually does.

A letter was forwarded to the National CFIDS Foundation from John Chavez from Chula Vista, California which said:

I was one of the participants in the Hemispherx Ampligen Phase III trial in San Diego, CA – roughly from June 1989 to February 20000. Of the approximately 25-30 participants (some dropped out very early) here in San Diego, I know that at least 4-6 people DROPPED OUT of the later stages (i.e. may months after the blind med vs. placebo infusions), me included, DUE TO SEVERE RECURRENCE AND WORSENING OF CFIDS MAJOR SYMPTOMS (e.g. body aches, sever fatigue, flu-like symptoms, sleep problems, cold sweats, etc.). We made it to and through at least two treadmill tests which caused some of us to relapse further.

We were given only superficial medical assessment and evaluation exams and the physician pretty much ignored complaints about worsening symptoms. Those conducting the trial tests refused to give us our own lab and other data from the trial. We are fairly sure that we were counted as drop-outs or not having completed the trial (true) – however, we doubt there was an indication of our adverse symptoms and our reason for dropping out of the trial (i.e. severe relapse an recurrence of major CFIDS symptoms).

Simply put: AMPLIGEN MADE US SICKER.

We kept track and in general contact with most of our fellow trial participants here. It is true that some small portion noticed some improvement. Of our overall group: Less than 25% noticed some improvement; maybe another 25-35% no noticeable change; maybe 25% slight relapse, and maybe 15-20% with severe relapse.

"I am not here to argue the numbers (a non-representative statistical population only yields incomplete and possibly erroneous date and conclusions). I am here to point out that:

"1. The trial failed to include and count many of those most adversely affected – they/we were simply eliminated from the trial population tabulations and shown as drop-outs, thus leaving mostly the healthy in the trial results.

"2. A notable number of us got significantly worse some time after the Ampligen was introduced – the onset and deterioration of symptoms was not random. ; Many of us have had CFIDS for 8-10 years by the time of the trials, most of us had achieved some overall equilibrium of the symptoms, and were well aware of normal variations of our symptoms – the onset and severity corresponded mostly to the infusions AND most of us improved somewhat after terminating the infusions.

"3. The medical interviews and Karnofsky tests to assess condition were very rudimentary and simplistic, and often lacked any reporting of well-known CFIDS symptoms.

"4. Those conducting the Ampligen trial refused to give us our lab results and medical records.

"I find it appalling that this drug, Ampligen, is even being considered for public use. Given the probability that Ampligen will exacerbate CFIDS symptoms in many, I cannot recommend it to anyone. The CFIDS community deserves complete data and information. Those continuing to promote or recommend Ampligen are being misled by faulty trials and data dressed up in the guise of complete and thorough testing.

"Be aware. Be warned."

A letter sent to the FDA from Estelle Altork, said, "I respectfully request that among the documents you look through to arrive at your decision, you add my letter to those documents. I was in the first group of 25 people in the Phase III Ampligen trial in San Diego, CA. The results that you will look at have been doctored, changed to fit what Hemispherx wants you to believe and are definitely not what has been the facts at the trial site. Of the 25 participants at our site at least 5 people dropped out in the later stages. Some of these people dropped out a week or two before the end of the trial because they were so very ill with worsening symptoms of Chronic Fatigue Immune Dysfunction Syndrome due to the drug. I was one of these people. We made it through to the last treadmill test. The medical supervision given by a Dr. Mercandetti in Hillcrest, San Diego was pitiful and superficial at best. He ignored our complaints, some of them very severe. We were promised our test results two years after the trial was over. Even though we wrote to Hemispherx Biopharma, we never received an answer or the test results.

"From our group of 25, there may have been 3 people that were helped, about 25% had no noticeable change, which is probably normal in a double blind test. 25% had a slight relapse and 25% had a very severe relapse. If only one eighth of our group seemed to be helped, does this justify putting a drug on the market? Incidentally, those of us that had a severe relapse, felt that our health got worse after getting off of the drug Ampligen. We are still in touch with those who were on this trial.

"We feel that the trial failed to include and count many of those most adversely affected. They were simply eliminated from the trial population tabulations, thus leaving mostly the healthy in the Phase III trial results. There is another very disturbing fact that has come to my attention. Included in the Board of Directors for Hemispherx Biopharma are two CFIDS doctors -- Dr. Anthony Komaroff and Dr. Charles Lapp. These two doctors were working on research and treating CFIDS patients and now they are on the Board of Hemispherx Biopharma?? I feel this is a conflict of interest and something that needs looking into. Thank you for your time and I appreciate your listening to a patient who became more severely ill from the Ampligen trial."

[Ed. Note: Chavez went from a productive engineer and sales executive to bankruptcy losing his home, savings and retirement (401K) and, ultimately, his marriage of 25 years. He and Estelle were in the same Phase III trial of Ampligen.]

The National CFIDS Foundation * 103 Aletha Rd, Needham Ma 02492 * [phone] Fax [phone]
................................................................

http://www.investorshub.com/boards/read_msg.asp?message_id=8078533
Posted by: mick
In reply to: mick who wrote msg# 71312 Date:10/11/2005 7:53:18 PM
Post #of 71352

PART #2 ,,, HEB ,,, HEB. Alferon N Injection , THIS IS WHAT ATTRACTS ME TO HEB.

HEB ACQUIRED FROM Interferon Sciences, Inc. (IFSC.OB)

Hemispherx is already counting on FDA approval and is building a marketing team in this country. They acquired a Alferon N Injection from Interferon Biosciences just last year and have already contracted with nearly 100 sales representatives.

IFSC WAS PAID IN SHARES FROM HEB FOR THE ACQUISITION Alferon N Injection. THIS IS THE IMPORTANCE TO ME ABOUT HEB.

................................................................

http://www.investorshub.com/boards/read_msg.asp?message_id=8078536

Posted by: mick
In reply to: mick who wrote msg# 71316 Date:10/11/2005 7:54:06 PM
Post #of 71352

PART #3-HEB ,,, THESE ARE MY OPINIONS FROM THESE READINGS.